KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $249.4 million.

  • Acadia Pharmaceuticals' Non-Current Assets rose 34.87% to $254.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.3 million, marking a year-over-year increase of 34.87%. This contributed to the annual value of $249.4 million for FY2024, which is 87.79% up from last year.
  • Acadia Pharmaceuticals' Non-Current Assets amounted to $249.4 million in FY2024, which was up 87.79% from $132.8 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Non-Current Assets registered a high of $249.4 million during FY2024, and its lowest value of $65.0 million during FY2020.
  • Over the past 3 years, Acadia Pharmaceuticals' median Non-Current Assets value was $132.8 million (recorded in 2023), while the average stood at $154.0 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Non-Current Assets soared by 183.43% in 2020, and later decreased by 2.95% in 2022.
  • Acadia Pharmaceuticals' Non-Current Assets (Yearly) stood at $65.0 million in 2020, then increased by 26.61% to $82.3 million in 2021, then decreased by 2.95% to $79.9 million in 2022, then spiked by 66.30% to $132.8 million in 2023, then spiked by 87.79% to $249.4 million in 2024.